Hos de 289 individer hvis immunisering blev undersøgt var sero- beskyttelsesraten (SP i nedenstående tabel) for hepatitis B signifikant højere ved 2 og 6 måneder med 3 dosis vaccinen end for Ambirix.
For the 289 subjects evaluable for immunogenicity, seroprotection rates (SP in the table below) against hepatitis B were significantly higher at months 2 and 6 with the three-dose vaccine than with Ambirix.